1. 本轮融资由Bain Capital Life Sciences领投，老股东及新投资人积极跟投
2. 融资所得款项将用于推进致力于骨骼、关节和肌肉重症疾病领域的AGA2118、AGA2115、AGA111和其他在研管线的新药研发3. Norbert Riedel博士将加入公司董事会
2024年12月11日，中国广东广州和美国加州WOODLAND HILLS：安济盛生物，一家专注于骨骼、关节和肌肉重症疾病领域的创新药物研发公司，今日宣布完成由Bain Capital Life Sciences领投的1.2亿美元C轮融资。
参与本轮投资的包括新投资人Janus Henderson及老股东奥博资本、三正健康投资、涌铧投资、君联资本和骊宸投资。C轮融资所得款项将用于支持安济盛的创新药物管线，致力于开发针对骨骼、关节和肌肉重症疾病领域的差异化创新治疗方案。
随此次融资完成，经由Bain Capital Life Sciences推荐的Norbert Riedel博士将加入安济盛董事会。作为一位在生物制药领域享有盛誉的科学家和高管，Riedel博士将凭借数十年的管理经验为安济盛注入强大力量。Riedel博士是Jazz Pharmaceuticals和Eton Pharmaceuticals的董事会成员，且担任Alcyone Therapeutics董事会主席并于近日结束了Cerevel Therapeutics的董事会任期。Riedel博士曾创立Aptinyx, Inc，并担任过于2015年被 Allergan收购的Naurex公司首席执行官。Riedel博士也曾于Baxter International和 Hoechst-Marion Roussel（现为Sanofi）担任高级管理职务。Riedel博士拥有法兰克福大学生物化学学位和生物化学博士学位。
安济盛正在推进AGA2118和AGA2115用于治疗骨质疏松症和成骨不全症（OI）的全球临床开发。这两种双特异性抗体能够特异性结合硬骨抑素和DKK1，代表了能同时增加骨形成和减少骨吸收的新一代骨骼疾病双效疗法。安济盛期待这两种双特异性药物将有助于促进患者更强健且更有序的骨骼发育。同时，公司正在开发促进椎间盘退行性疾病患者脊柱融合的生物制剂AGA111。
安济盛正在招募绝经后女性骨质疏松症患者参与AGA2118临床II期试验（NCT06577935）。用于治疗成骨不全症（OI）的AGA2115目前处于临床I期试验阶段（NCT06086613）。一项探索AGA111在腰椎椎间融合术患者中应用的临床III期试验（NCT06115512）正在进行中。
“ 关于安济盛生物 ”
安济盛生物是一家专注于骨骼、关节和肌肉重症疾病领域的创新药物研发公司，目前有3款生物大分子候选药物正处于临床研究阶段，旨在治疗骨质疏松症、成骨不全（OI）和脊柱融合。安济盛生物以对骨骼肌肉系统疾病致病机制的科学洞见和在创新药物开发上积累的丰富成功经验，致力为患者带来优效和安全的全新治疗方案。
Angitia Biopharmaceuticals Announces $120 Million Series C Financing
- Financing led by Bain Capital Life Sciences with significant participation from existing and new investors
- Proceeds will support the development of AGA2118, AGA2115, AGA111 and other pipeline assets for the treatment of serious musculoskeletal diseases
- Norbert Riedel, Ph.D., will join the Board of Directors
WOODLAND HILLS, Calif. December 11, 2024 – Angitia Biopharmaceuticals (“Angitia” or “the Company”), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, today announced the closing of a $120 million Series C financing round. Bain Capital Life Sciences led the financing, with participation from new investor Janus Henderson and existing investors OrbiMed, 3H Health Investment, Yonghua Capital, Legend Capital, and Elikon Venture. Proceeds from the Series C will support Angitia’s robust pipeline of novel, differentiated treatments for serious musculoskeletal diseases.
“The broad support for Angitia in this financing validates the hard work of our team, the clinical progress of our programs, and the quality of our emerging data,” said Dr. David Ke, M.D., Chief Executive Officer of Angitia. “We express gratitude to our investors, new and returning, for their support in our journey to provide novel and effective treatments for patients with musculoskeletal disease, and we look forward to continuing to execute on developing these valuable medicines.”
Angitia is advancing AGA2118 and AGA2115, bispecific antibodies targeting sclerostin and DKK1, through clinical development for osteoporosis and osteogenesis imperfecta (OI), respectively. The two molecules represent the next generation of dual-acting treatments for skeletal disease, increasing bone formation and decreasing bone resorption. With these two bispecifics, Angitia seeks to promote stronger, more organized skeletal development in patients. The Company is also developing AGA111, a biologic to promote spinal fusion in patients with degenerative disc disease.
In conjunction with the financing, Dr. Norbert Riedel, Ph.D., will join the Company’s Board of Directors. A seasoned scientist and biopharmaceutical executive, he brings decades of leadership experience to Angitia. Dr. Riedel serves on the board of directors of Jazz Pharmaceuticals and Eton Pharmaceuticals and is Chairman of the Board of Alcyone Therapeutics. He recently completed his tenure on the board of Cerevel Therapeutics. Dr. Riedel previously founded Aptinyx, Inc. and served as CEO of Naurex, which was acquired by Allergan in 2015. He also held senior roles at Baxter International and Hoechst-Marion Roussel (now Sanofi). Dr. Riedel holds a diploma in biochemistry and a Ph.D. in biochemistry from the University of Frankfurt.
Angitia is enrolling patients in a Phase 2 study in postmenopausal women with AGA2118 (NCT06577935). AGA2115 is being developed for the treatment of OI and is currently in a first-in-human study (NCT06086613). AGA111 is being explored for use in patients undergoing lumbar interbody fusion in a Phase 3 study (NCT06115512).
About Angitia Biopharmaceuticals
Angitia Biopharmaceuticals is a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases. Angitia is currently studying 3 biologic product candidates in the clinic for the treatment of osteoporosis, osteogenesis imperfecta (OI), and spinal fusion. Leveraging the team's extensive experience and scientific acumen in novel drug development, Angitia is committed to providing groundbreaking therapies to satisfy key unmet medical needs.
Learn more at www.angitiabio.com.
